01
Intentional oversight
Select human involvement based on risk, autonomy, decision authority, and the consequences of error.
White paper · October 2026
Rethinking human-in-the-loop for Veeva Vault AI and Veeva Falcon
Get the 18-page white paper18 pages 9 sections Human oversight in practice

The approval paradox
As AI moves from assisting with individual tasks to executing broader workflows, human oversight must evolve with it. Reviewers need the evidence, expertise, and authority to detect and prevent the errors that matter.
This paper explores how to preserve meaningful judgment, accountability, and control as Veeva Vault AI and Veeva Falcon take on more of the work—without defaulting to an approval step for every task.
From principles to practice
01
Select human involvement based on risk, autonomy, decision authority, and the consequences of error.
02
Retain sufficient evidence to reconstruct agent activity, human decisions, and regulated outcomes.
03
Evaluate the combined human-AI process under realistic conditions and monitor whether its controls continue to work.
Prove the control works
The paper identifies practical monitoring measures for the combined human-AI process. These are measures to track, not claimed performance outcomes.
Track consequential errors that reviewers miss to test whether the control provides its intended protection.
Examine reviewer patterns. Low rejection rates may reflect better AI performance—or declining attention.
Check whether exceptions are detected, routed, and resolved before unacceptable consequences occur.
“Human oversight should be treated as a control whose performance can be evaluated, not as a procedural label.”Beyond the Approval Button, page 4
Get the white paper
Explore the approval paradox, regulatory expectations, vendor evidence, accountability, and testing the effectiveness of the human-AI process.
18-page PDF · USDM Life Sciences · October 2026
The paper distinguishes regulatory requirements, draft guidance, and design references. Applicability depends on intended use; platform capabilities vary by release.
Contributors
Principal Consultant
Vice President of Strategy and Operations
Source: USDM Life Sciences, Beyond the Approval Button, October 2026. General information, not legal, regulatory, or compliance advice.